share_log

Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.7%)

Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.7%)

Arcutis Biotherapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-BlackRock, Inc.(7.7%)
美股SEC公告 ·  11/09 11:18

Moomoo AI 已提取核心信息

BlackRock, Inc., a major investment management corporation based in Delaware, has filed an amended Schedule 13G with the Securities and Exchange Commission on November 8, 2024, indicating a significant ownership stake in Arcutis Biotherapeutics, Inc. The filing reveals that BlackRock now beneficially owns 9,029,624 shares of Arcutis Biotherapeutics' common stock, which represents 7.7% of the company's class of securities. This position gives BlackRock sole voting power over 8,893,485 shares and sole dispositive power over the entire 9,029,624 shares held. The filing, which is required due to the change in ownership percentage, indicates that BlackRock's investment is held in the ordinary course of business and not with the purpose of changing or influencing the control of Arcutis Biotherapeutics.
BlackRock, Inc., a major investment management corporation based in Delaware, has filed an amended Schedule 13G with the Securities and Exchange Commission on November 8, 2024, indicating a significant ownership stake in Arcutis Biotherapeutics, Inc. The filing reveals that BlackRock now beneficially owns 9,029,624 shares of Arcutis Biotherapeutics' common stock, which represents 7.7% of the company's class of securities. This position gives BlackRock sole voting power over 8,893,485 shares and sole dispositive power over the entire 9,029,624 shares held. The filing, which is required due to the change in ownership percentage, indicates that BlackRock's investment is held in the ordinary course of business and not with the purpose of changing or influencing the control of Arcutis Biotherapeutics.
贝莱德,一家总部位于特拉华州的主要投资管理公司,于2024年11月8日向证券交易委员会提交了修订后的13G表,表明其在arcutis biotherapeutics公司持有重要的股权。提交的文件显示,贝莱德现在有9029624股arcutis biotherapeutics普通股的有利拥有权,占该公司证券类别的7.7%。这个头寸使贝莱德对8893485股拥有唯一的表决权,对所持的9029624股拥有唯一的处置权。这份文件是因所有权比例的变化而必需的,表明贝莱德的投资是以正常业务方式持有的,并非出于改变或影响arcutis biotherapeutics控制权的目的。
贝莱德,一家总部位于特拉华州的主要投资管理公司,于2024年11月8日向证券交易委员会提交了修订后的13G表,表明其在arcutis biotherapeutics公司持有重要的股权。提交的文件显示,贝莱德现在有9029624股arcutis biotherapeutics普通股的有利拥有权,占该公司证券类别的7.7%。这个头寸使贝莱德对8893485股拥有唯一的表决权,对所持的9029624股拥有唯一的处置权。这份文件是因所有权比例的变化而必需的,表明贝莱德的投资是以正常业务方式持有的,并非出于改变或影响arcutis biotherapeutics控制权的目的。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息